February 25, 2021

Reactive Unilateral Axillary Adenopathy Following COVID-19 Vaccination

As vaccine availability increases, expect to see more complaints of palpable masses and abnormal results from routine breast screening

21-WHI-2064882_CQD_650x450_1

By Laura Dean, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Case report

A 32-year-old woman is referred to breast radiology by her primary care provider for evaluation of palpable lumps in the left axilla. Ultrasound of the area shows multiple enlarged lymph nodes with cortical thickening in the left axilla. She reports a COVID-19 vaccine in the left arm 10 days prior. The patient’s unilateral axillary adenopathy is likely a reaction to the vaccination; however, short-term follow-up is warranted. The patient is asked to return to radiology in 4-12 weeks, at which point we will reevaluate. If the unilateral axillary adenopathy persists at follow-up, we would consider lymph node sampling to rule out malignancy.

Abnormally thickened axillary nodes

Normal node for comparison

Reactive unilateral axillary adenopathy

A small, but not insignificant number of people develop unilateral axillary adenopathy in the days following vaccination against SARS-CoV-2, the virus that causes COVID-19.

In general, any vaccine could cause this sort of reactive lymph node enlargement. Looking back, this phenomenon was documented occasionally as a reaction from other vaccines, including measles, smallpox and anthrax. Lymphadenopathy is an expected part of a healthy immune response. That said, this adenopathy seems much more robust with our current COVID-19 vaccines than in historical vaccines.

Results from the Moderna trials demonstrate that, following the second dose, axillary adenopathy occurred in 16% of women aged 18-64 years. The incidence reported by Pfizer is less as researchers only collected unsolicited axillary symptoms; however, the Pfizer data does provide insight into the time course of lymphadenopathy: generally it was reported 2-4 days following vaccination and the mean duration was 10 days.

Advertisement

An uncommon finding

Lymph node abnormality is an uncommon finding in screening breast exams. Specifically, we only see lymph node abnormality in about 0.02%-0.04% of screening mammograms. As COVID-19 vaccinations become more readily available to the broader population, we expect to have more patients reporting these palpable masses or with axillary adenopathy on mammogram.

Changes to current practice

After identifying axillary adenopathy on a screening mammogram, further assessment of the ipsilateral breast is warranted, and should include a full medical history (including information about whether or not the patient received the COVID-19 vaccine, which vaccine they received, when, and in which arm). The Society for Breast Imaging currently recommends a short-term follow-up exam 4-12 weeks following the second vaccine dose to rule out malignancy.

At Cleveland Clinic, one of the first things we did in response to this was to amend our patient intake form. Now, in addition to asking for a personal breast cancer history and family history, we also ask if the patient has had a recent COVID-19 vaccine injection. We document the manufacturer, date of injection, and the arm in which the patient received it. Currently, for every screening mammogram I review, there’s a note from the technologist that says: “COVID-19 vaccine? Yes/No.”

If we see lymphadenopathy, we perform ultrasound to establish a baseline, and then bring the patients back several weeks after the second dose to compare the imagining to ensure that the nodes have returned to normal.

Advertisement

We do not want these reports to discourage patients from getting the vaccine

It’s important for physicians to stress that screening mammograms should not be postponed. Asymptomatic patients seeking routine screening may wish to schedule their mammogram 4-6 weeks following the COVID-19 vaccine. However, we do not want to discourage patients from receiving the vaccine. If patients are offered the opportunity for vaccination, they should take it. Lymphadenopathy does not occur in a majority of patients, and if it does, we will follow up as needed.

Last year, many patients postponed important screenings because of the pandemic. Another message we need to be sharing widely with our patients is that it is safe to have a mammogram. We have a year of experience providing healthcare during a pandemic in a way that keeps our patients and caregivers safe. We have universal masking, health screenings at each entrance and physical spacing throughout our facilities. Yes, it is safe to seek care.

About Dr. Dean:Laura Dean, MD, is a diagnostic radiologist who specializes in breast imaging.

Related Articles

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Ad